<DOC>
	<DOCNO>NCT00712205</DOCNO>
	<brief_summary>The investigator want test hypothesis , vitamin D3 improve pulmonary function quality life patient asthma relatively resistant glucocorticoid .</brief_summary>
	<brief_title>Vitamin D Treatment Severe Asthma</brief_title>
	<detailed_description>Glucocorticoids first-line antiinflammatory treatment asthma . Their multiple inhibitory property , include inhibition Th2 cytokine synthesis , likely contribute clinical efficacy . Glucocorticoids also enhance IL-10 production vitro human CD4+ CD8+ T cell , glucocorticoid treatment induces synthesis IL-10 airway cell asthmatic patient . IL-10 potent antiinflammatory immunosuppressive lead profound inhibition Th1 cell-mediated immunity . A proportion asthmatic patient fails benefit oral glucocorticoid therapy thus denote glucocorticoid-resistant ( SR , derive `` steroid resistant '' ) insensitive asthma . It demonstrate CD4+ T cell SR asthma patient fail induce IL-10 synthesis follow vitro stimulation presence dexamethasone compare glucocorticoid-sensitive counterpart ( SS , derive `` steroid sensitive '' ) , suggest link induction IL-10 synthesis clinical efficacy glucocorticoid . One potential source IL-10 Tregs , control function effector T cell . Glucocorticoids enhance production IL-10 polyclonally stimulate T cell cell inhibit IFN- production human CD4+ T cell IL-10-dependent manner . In mouse human combination dexamethasone calcitriol , active form vitamin D3 , induce high number IL-10-producing T cell make negligible amount Th1 Th2 cytokine . Xystrakis et al . ( 57 ) show IL-10-secreting Tregs inhibit cytokine production previously activate allergen-specific Th2 cell pretreating T cell IL-10 add vitamin D3 cell culture reverse defect enhance IL-10 production Tregs asthmatic patient resistant glucocorticoid therapy . These manipulation increase IL-10 production level comparable observed patient respond well therapy . IL-10 increase glucocorticoid receptor expression , author propose mechanism IL-10 overcome glucocorticoid-resistant patient defect IL-10 synthesis . This strongly suggest vitamin D3 could potentially increase therapeutic response glucocorticoid SR patient . We want test hypothesis , vitamin D3 improve pulmonary function quality life patient asthma relatively resistant glucocorticoid .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>20 outpatient either sex , age ≥18 year , history persistent asthma define American Thoracic Society ( ATS ) eligible entry study . Additionally , patient must previously treat ICS least 4 week stable dose equivalent ≥400 ug/day beclomethasone dipropionate . Patients require forced expiratory volume 1 ( FEV1 ) 4085 % predict normal use inhale bronchodilator demonstrate least one following : improvement FEV1 ≥ 12 % ≥ 200 ml within 1530 min inhalation salbutamol 200400 ug ; airway hyperresponsiveness methacholine cause 20 % decline FEV1 ( PC20 FEV1 ) concentration &lt; 16 mg/ml ; diurnal peak expiratory flow ( PEF ) variability ≥ 15 % least 3 7 day randomization . Patients either exacerbation asthma respiratory tract infection within 6 week admission hospital asthma within 6 week study exclude . Also patient eligible &gt; 3 night awakening due asthma required treatment shortacting betamimetics 3 day require &gt; = 12 puffs/d shortacting betamimetics 7days randomization visit . Patients also exclude use medication great potency inhale steroid , e.g.not leukotriene inhibitor antiIgE ( Xolair® ) . Patients chronic obstructive pulmonary disease current former smoker &gt; 10 packyears</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Vitamin D</keyword>
</DOC>